AeroPace System
Lungpacer Medical USA, Inc. · Decision date Sep 25, 2026
What did the FDA approve?
The FDA database lists decision APPR for supplement P240012/S008 to AeroPace® System, submitted by Lungpacer Medical USA, Inc., dated 2026-09-25. The supplement type is Real-Time Process with reason Process Change - Manufacturer/Sterilizer/Packager/Supplier. The source statement describes approval for changes to the temperature control components in the Neurostimulation Console and packaging changes for the Console. The product code is SDL, categorized as a transvenous temporary phrenic nerve stimulator under Anesthesiology.
The P240012 prefix links this supplement to the original PMA of that number, but a supplement is not a new approval of the whole system. The statement reports a regulatory decision on specified component and packaging changes; it does not establish safety or clinical effectiveness. Specifics absent from the record include which temperature control components changed, the nature of the packaging changes, and any supporting data.
FDA approval order statement
Approval for changes to the temperature control components in the Neurostimulation Console and packaging changes for the Console.
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Anesthesiology
- Decision date
- Sep 25, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P240012/S008
- Regulatory pathway
- PMA supplement
- Applicant
- Lungpacer Medical USA, Inc.
- Product code
- SDL
- Decision code
- APPR
- Decision date
- Sep 25, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Transvenous temporary phrenic nerve stimulator.
- Applicant
- Lungpacer Medical USA, Inc.
- Product code
- SDL
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P240012. Subsequent supplements may change the device or its indications.
FDA decision timeline
P240012 · Original PMA
AeroPace System
P240012/S008 received
Application receipt date recorded by FDA.
P240012/S008 · FDA decision
Real-Time Process
Timeline entries are records held by MedtechLedger for P240012. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P240012
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
AeroPace SystemP240012 | Lungpacer Medical USA, Inc. | PMA approval | Dec 4, 2024 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Lungpacer Medical USA, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 260 Sierra Dr., Suite 116, Exton, PA, 19341
Sources and methodology
- Original FDA record: P240012/S008
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records